I always think of Johnson & Johnson as one of the good guys, so it was very disheartening to read this article in the New York Times (free reg. req'd): Lucrative Drug, Danger Signals and the F.D.A. about its heartburn drug, Propulsid. A snip:
Propulsid's history has striking parallels with the painkillers now at the
center of controversy. Dozens of studies sponsored by Johnson & Johnson that
might have warned doctors away were never published, just as the pharmaceutical
manufacturer Pfizer
failed to publish an early study of Celebrex that indicated a heart risk. And
Johnson & Johnson was able to delay and soften some proposed label changes,
just as Merck
later did with Vioxx.
0 comments
Hide comments